Teriparatide is a medicine used to help build bone density in people with osteoporosis. It's given as an injection under the skin. It helps strengthen bones to reduce the risk of fractures.
Every report comes from a Lived member, sent anonymously.
Have you tried Forteo (Teriparatide) for Osteoporosis?
Teriparatide, sold as Forteo and also available as generic teriparatide pens, is a daily injection that treats osteoporosis by helping the body build new bone. It is approved for postmenopausal women with osteoporosis who are at high risk of breaking a bone, for men with osteoporosis at high risk, and for men and women whose osteoporosis is linked to taking steroid (glucocorticoid) medicines such as prednisone long term. High risk usually means a previous fracture from osteoporosis or several risk factors together. It is also used when other osteoporosis treatments have not worked or could not be tolerated. Most people with osteoporosis start with a bisphosphonate, a group of pills or infusions such as alendronate (Fosamax) that slow bone loss. Teriparatide is usually reserved for people at very high risk, such as someone who has had a recent fracture or several spine fractures, because it is more demanding to use and considerably more expensive. Teriparatide should not be confused with Yorvipath (palopegteriparatide), a different, long-acting medicine used for hypoparathyroidism, a condition in which the body makes too little parathyroid hormone.
Bone is constantly being broken down and rebuilt. Most osteoporosis medicines work by slowing the breakdown side of that cycle. Teriparatide works on the building side instead. It is a lab-made copy of the active part of parathyroid hormone, the body's main regulator of calcium in bone and the kidneys. Constantly high levels of this hormone, as happen when the parathyroid glands are overactive, weaken bone. A short daily pulse from an injection has the opposite effect: it stimulates the cells that lay down new bone more than the cells that remove it. Over months, this adds bone mass, particularly in the spine, and increases bone strength. Bone density in the spine typically starts to rise within about three months.
Teriparatide is injected once a day under the skin of the thigh or abdomen using a prefilled pen. The usual dose is the same for everyone, so the main thing to learn is the pen itself; a nurse or pharmacist normally shows people how to use it before they start. Each pen holds 28 daily doses and must be thrown away 28 days after first use, even if some liquid remains. The pen is kept in the refrigerator, not frozen, and returned there right after each injection. Do not transfer the medicine into a separate syringe or share a pen. Some people feel lightheaded or notice a racing heartbeat within a few hours of the first few doses, because blood pressure can dip briefly when standing. For that reason, take the early doses somewhere you can sit or lie down, and stay seated until it passes. If it keeps happening or gets worse, check with the prescriber before continuing. Calcium and vitamin D are usually taken alongside teriparatide when diet alone does not provide enough.
The most common side effects are joint pain, general aches and nausea. Dizziness, leg cramps and pain, swelling or bruising where the needle went in can also occur. These are often mild, and the dizziness tends to be worst with the first doses. Teriparatide raises blood calcium for a few hours after each injection, and in some people the level climbs too high. Persistent nausea, vomiting, constipation, low energy or muscle weakness can be signs of high calcium and are worth reporting to the care team. Serious allergic reactions are rare. Stop the medicine and get medical help promptly for hives or a widespread rash; swelling of the face, lips, tongue or throat, or trouble breathing, is an emergency that calls for 911.
In rat studies, teriparatide increased the rate of osteosarcoma, a bone cancer. Large observational studies in people have not shown a higher risk, but the medicine is still avoided in anyone whose baseline risk of osteosarcoma is already raised: children and young adults whose bones are still growing, people with Paget's disease of bone or other metabolic bone diseases, people with bone cancer or cancer that has spread to bone, anyone who has had radiation therapy involving the skeleton, and people with inherited conditions that predispose to osteosarcoma. Because it raises calcium, teriparatide is avoided in people who already have high calcium, for example from primary hyperparathyroidism (an overactive parathyroid gland). It needs careful thought in people with active or recent kidney stones. A rare, painful skin condition caused by calcium deposits (calciphylaxis) has been reported, more often in people with kidney failure, autoimmune disease or those taking warfarin or steroid medicines; new or worsening painful skin sores should be reported. People who take digoxin, a heart medicine for heart failure or irregular rhythm, should tell the prescriber, since higher calcium can make digoxin's toxic effects more likely. Teriparatide is not recommended during breastfeeding and is usually stopped if pregnancy occurs.
Teriparatide is a time-limited treatment. Bone density usually improves over the first months, but people typically feel no different day to day; the benefit is fewer future fractures rather than a change you can sense. In the main trial in postmenopausal women, new spine fractures over about a year and a half fell from roughly 14 in 100 women on placebo to 5 in 100 on teriparatide, and other fractures were also reduced. Evidence that it prevents hip fractures specifically is less clear. In men, the approval is based on gains in bone density rather than fracture results. Total use over a lifetime is generally limited to 2 years, with longer use considered only if fracture risk remains or again becomes high. The daily injections and the cost, which is higher than other osteoporosis medicines, are the main practical trade-offs, and side effects lead some people to stop early. What happens after teriparatide matters as much as the course itself. Bone gained can be lost quickly once injections stop, raising fracture risk again, so guidelines recommend moving straight on to a medicine that slows bone breakdown, such as a bisphosphonate. Follow-up with the care team is the time to agree on that next medicine before the last pen runs out.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Forteo (Teriparatide), what you've noticed, or ask the community a question.